Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Rare disease patients in China anticipate the sunlight of legislation.

Gao JJ, Song PP, Tang W.

Drug Discov Ther. 2013 Jun;7(3):126-8.

2.

A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.

Liu BC, He L, He G, He Y.

J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.

PMID:
21119648
3.

Intractable and rare diseases research in Asia.

Song P, Gao J, Inagaki Y, Kokudo N, Tang W.

Biosci Trends. 2012 Apr;6(2):48-51.

4.

Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.

Song P, Gao J, Inagaki Y, Kokudo N, Tang W.

Intractable Rare Dis Res. 2012 Feb;1(1):3-9. doi: 10.5582/irdr.2012.v1.1.3. Review.

5.

Legal assessment of current situation on orphan patients in Lithuania.

Spokiene I.

Medicina (Kaunas). 2008;44(8):571-6. Review.

6.

A regulatory overview about rare diseases.

Llinares J.

Adv Exp Med Biol. 2010;686:193-207. doi: 10.1007/978-90-481-9485-8_12. Review.

PMID:
20824447
7.

Drugs for rare diseases: mixed assessment in Europe.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):36-42.

PMID:
17323539
8.

Towards government-funded special biomedical research programs to combat rare diseases in China.

Chen K, Yao L, Liu Z.

Biosci Trends. 2015 Apr;9(2):88-90. doi: 10.5582/bst.2015.01048. Epub 2015 Apr 21. Review.

9.

Developing treatments for inborn errors: incentives available to the clinician.

Haffner ME.

Mol Genet Metab. 2004 Apr;81 Suppl 1:S63-6.

PMID:
15050976
10.

[Rare diseases--a problem of healthcare-related social security law].

Rixen S.

Z Evid Fortbild Qual Gesundhwes. 2008;102(1):31-6. German.

PMID:
19009939
11.

Current progress in the management of rare diseases and orphan drugs in China.

Gong S, Jin S.

Intractable Rare Dis Res. 2012 May;1(2):45-52. doi: 10.5582/irdr.2012.v1.2.45. Review.

12.
13.

[Authorization and reimbursement of orphan drugs in an international comparison].

Roll K, Stargardt T, Schreyögg J.

Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Review. German.

PMID:
20848380
14.

[Current views on rare diseases research and orphan drugs development].

Jiang J, Li J, Liu W.

Sheng Wu Gong Cheng Xue Bao. 2011 May;27(5):724-9. Review. Chinese.

PMID:
21845839
15.

Translation of rare disease research into orphan drug development: disease matters.

Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL.

Drug Discov Today. 2009 Dec;14(23-24):1166-73. doi: 10.1016/j.drudis.2009.09.008. Epub 2009 Oct 7. Review.

PMID:
19818412
16.

[Global strategy for rare and intractable diseases].

Kawashima Kodama T.

Rinsho Shinkeigaku. 2013;23(11):1283-6. Japanese.

PMID:
24291960
17.

European regulation on orphan medicinal products: 10 years of experience and future perspectives.

Committee for Orphan Medicinal Products and the European Medicines, Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N'Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, Lhoir A, Todorova M, Kkolos I, Kubáčková K, Bosch-Traberg H, Tillmann V, Saano V, Héron E, Elbers R, Siouti M, Eggenhofer J, Salmon P, Clementi M, Krieviņš D, Matulevičiene A, Metz H, Vincenti AC, Voordouw A, Dembowska-Bagińska B, Nunes AC, Saleh FM, Foltánová T, Možina M, Torrent i Farnell J, Beerman B, Mariz S, Evers MP, Greene L, Thorsteinsson S, Gramstad L, Mavris M, Bignami F, Lorence A, Belorgey C.

Nat Rev Drug Discov. 2011 May;10(5):341-9. doi: 10.1038/nrd3445.

PMID:
21532564
18.

[Orphan drugs and orphan diseases].

Campos-Castelló J.

Rev Neurol. 2001 Aug 1-15;33(3):216-20. Review. Spanish.

PMID:
11588712
19.

[Orphan drugs: availability, reliability and reimbursement].

Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.

Ned Tijdschr Geneeskd. 2012;156(17):A4252. Dutch.

PMID:
22531041
20.

A proposal to improve the supply of orphan drugs.

Minghetti PM, Giudici EM, Montanari L.

Pharmacol Res. 2000 Jul;42(1):33-7.

PMID:
10860632
Items per page

Supplemental Content

Write to the Help Desk